The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals

Reduced cervical cancer risk and decreased yield of precancer per screen

Michelle I. Silver, Mark Schiffman, Barbara Fetterman, Nancy E. Poitras, Julia C. Gage, Nicolas Wentzensen, Thomas Lorey, Walter K. Kinney, Philip E. Castle

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

BACKGROUND: The objective of cervical screening is to detect and treat precancer to prevent cervical cancer mortality and morbidity while minimizing overtreatment of benign human papillomavirus (HPV) infections and related minor abnormalities. HPV/cytology cotesting at extended 5-year intervals currently is a recommended screening strategy in the United States, but the interval extension is controversial. In the current study, the authors examined the impact of a decade of an alternative, 3-year cotesting, on rates of precancer and cancer at Kaiser Permanente Northern California. The effect on screening efficiency, defined as numbers of cotests/colposcopy visits needed to detect a precancer, also was considered. METHODS: Two cohorts were defined. The “open cohort” included all women screened at least once during the study period; > 1 million cotests were performed. In a fixed “long-term screening cohort,” the authors considered the cumulative impact of repeated screening at 3-year intervals by restricting the cohort to women first cotested in 2003 through 2004 (ie, no women entering screening later were added to this group). RESULTS: Detection of cervical intraepithelial neoplasia 3/adenocarcinoma in situ (CIN3/AIS) increased in the open cohort (2004-2006: 82.0/100,000 women screened; 2007-2009: 140.6/100,000 women screened; and 2010-2012: 126.0/100,000 women screened); cancer diagnoses were unchanged. In the long-term screening cohort, the detection of CIN3/AIS increased and then decreased to the original level (2004-2006: 80.5/100,000 women screened; 2007-2009: 118.6/100,000 women screened; and 2010-2012: 84.9./100,000 women screened). The number of cancer diagnoses was found to decrease. When viewed in terms of screening efficiency, the number of colposcopies performed to detect a single case of CIN3/AIS increased in the cohort with repeat screening. CONCLUSIONS: Repeated cotesting at a 3-year interval eventually lowers population rates of precancer and cancer. However, a greater number of colposcopies are required to detect a single precancer. Cancer 2016;122:3682-6.

Original languageEnglish (US)
Pages (from-to)3682-3686
Number of pages5
JournalCancer
Volume122
Issue number23
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

Uterine Cervical Neoplasms
Cell Biology
Population
Colposcopy
Cervical Intraepithelial Neoplasia
Neoplasms
Papillomavirus Infections
Morbidity
Mortality
Adenocarcinoma in Situ

Keywords

  • biopsy
  • cervical cancer
  • cervical intraepithelial neoplasia
  • colposcopy
  • cotest
  • human papillomavirus
  • screening

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals : Reduced cervical cancer risk and decreased yield of precancer per screen. / Silver, Michelle I.; Schiffman, Mark; Fetterman, Barbara; Poitras, Nancy E.; Gage, Julia C.; Wentzensen, Nicolas; Lorey, Thomas; Kinney, Walter K.; Castle, Philip E.

In: Cancer, Vol. 122, No. 23, 01.12.2016, p. 3682-3686.

Research output: Contribution to journalArticle

Silver, Michelle I. ; Schiffman, Mark ; Fetterman, Barbara ; Poitras, Nancy E. ; Gage, Julia C. ; Wentzensen, Nicolas ; Lorey, Thomas ; Kinney, Walter K. ; Castle, Philip E. / The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals : Reduced cervical cancer risk and decreased yield of precancer per screen. In: Cancer. 2016 ; Vol. 122, No. 23. pp. 3682-3686.
@article{28b174bb9fc842dfaa2ada7f8274339c,
title = "The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen",
abstract = "BACKGROUND: The objective of cervical screening is to detect and treat precancer to prevent cervical cancer mortality and morbidity while minimizing overtreatment of benign human papillomavirus (HPV) infections and related minor abnormalities. HPV/cytology cotesting at extended 5-year intervals currently is a recommended screening strategy in the United States, but the interval extension is controversial. In the current study, the authors examined the impact of a decade of an alternative, 3-year cotesting, on rates of precancer and cancer at Kaiser Permanente Northern California. The effect on screening efficiency, defined as numbers of cotests/colposcopy visits needed to detect a precancer, also was considered. METHODS: Two cohorts were defined. The “open cohort” included all women screened at least once during the study period; > 1 million cotests were performed. In a fixed “long-term screening cohort,” the authors considered the cumulative impact of repeated screening at 3-year intervals by restricting the cohort to women first cotested in 2003 through 2004 (ie, no women entering screening later were added to this group). RESULTS: Detection of cervical intraepithelial neoplasia 3/adenocarcinoma in situ (CIN3/AIS) increased in the open cohort (2004-2006: 82.0/100,000 women screened; 2007-2009: 140.6/100,000 women screened; and 2010-2012: 126.0/100,000 women screened); cancer diagnoses were unchanged. In the long-term screening cohort, the detection of CIN3/AIS increased and then decreased to the original level (2004-2006: 80.5/100,000 women screened; 2007-2009: 118.6/100,000 women screened; and 2010-2012: 84.9./100,000 women screened). The number of cancer diagnoses was found to decrease. When viewed in terms of screening efficiency, the number of colposcopies performed to detect a single case of CIN3/AIS increased in the cohort with repeat screening. CONCLUSIONS: Repeated cotesting at a 3-year interval eventually lowers population rates of precancer and cancer. However, a greater number of colposcopies are required to detect a single precancer. Cancer 2016;122:3682-6.",
keywords = "biopsy, cervical cancer, cervical intraepithelial neoplasia, colposcopy, cotest, human papillomavirus, screening",
author = "Silver, {Michelle I.} and Mark Schiffman and Barbara Fetterman and Poitras, {Nancy E.} and Gage, {Julia C.} and Nicolas Wentzensen and Thomas Lorey and Kinney, {Walter K.} and Castle, {Philip E.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1002/cncr.30277",
language = "English (US)",
volume = "122",
pages = "3682--3686",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals

T2 - Reduced cervical cancer risk and decreased yield of precancer per screen

AU - Silver, Michelle I.

AU - Schiffman, Mark

AU - Fetterman, Barbara

AU - Poitras, Nancy E.

AU - Gage, Julia C.

AU - Wentzensen, Nicolas

AU - Lorey, Thomas

AU - Kinney, Walter K.

AU - Castle, Philip E.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - BACKGROUND: The objective of cervical screening is to detect and treat precancer to prevent cervical cancer mortality and morbidity while minimizing overtreatment of benign human papillomavirus (HPV) infections and related minor abnormalities. HPV/cytology cotesting at extended 5-year intervals currently is a recommended screening strategy in the United States, but the interval extension is controversial. In the current study, the authors examined the impact of a decade of an alternative, 3-year cotesting, on rates of precancer and cancer at Kaiser Permanente Northern California. The effect on screening efficiency, defined as numbers of cotests/colposcopy visits needed to detect a precancer, also was considered. METHODS: Two cohorts were defined. The “open cohort” included all women screened at least once during the study period; > 1 million cotests were performed. In a fixed “long-term screening cohort,” the authors considered the cumulative impact of repeated screening at 3-year intervals by restricting the cohort to women first cotested in 2003 through 2004 (ie, no women entering screening later were added to this group). RESULTS: Detection of cervical intraepithelial neoplasia 3/adenocarcinoma in situ (CIN3/AIS) increased in the open cohort (2004-2006: 82.0/100,000 women screened; 2007-2009: 140.6/100,000 women screened; and 2010-2012: 126.0/100,000 women screened); cancer diagnoses were unchanged. In the long-term screening cohort, the detection of CIN3/AIS increased and then decreased to the original level (2004-2006: 80.5/100,000 women screened; 2007-2009: 118.6/100,000 women screened; and 2010-2012: 84.9./100,000 women screened). The number of cancer diagnoses was found to decrease. When viewed in terms of screening efficiency, the number of colposcopies performed to detect a single case of CIN3/AIS increased in the cohort with repeat screening. CONCLUSIONS: Repeated cotesting at a 3-year interval eventually lowers population rates of precancer and cancer. However, a greater number of colposcopies are required to detect a single precancer. Cancer 2016;122:3682-6.

AB - BACKGROUND: The objective of cervical screening is to detect and treat precancer to prevent cervical cancer mortality and morbidity while minimizing overtreatment of benign human papillomavirus (HPV) infections and related minor abnormalities. HPV/cytology cotesting at extended 5-year intervals currently is a recommended screening strategy in the United States, but the interval extension is controversial. In the current study, the authors examined the impact of a decade of an alternative, 3-year cotesting, on rates of precancer and cancer at Kaiser Permanente Northern California. The effect on screening efficiency, defined as numbers of cotests/colposcopy visits needed to detect a precancer, also was considered. METHODS: Two cohorts were defined. The “open cohort” included all women screened at least once during the study period; > 1 million cotests were performed. In a fixed “long-term screening cohort,” the authors considered the cumulative impact of repeated screening at 3-year intervals by restricting the cohort to women first cotested in 2003 through 2004 (ie, no women entering screening later were added to this group). RESULTS: Detection of cervical intraepithelial neoplasia 3/adenocarcinoma in situ (CIN3/AIS) increased in the open cohort (2004-2006: 82.0/100,000 women screened; 2007-2009: 140.6/100,000 women screened; and 2010-2012: 126.0/100,000 women screened); cancer diagnoses were unchanged. In the long-term screening cohort, the detection of CIN3/AIS increased and then decreased to the original level (2004-2006: 80.5/100,000 women screened; 2007-2009: 118.6/100,000 women screened; and 2010-2012: 84.9./100,000 women screened). The number of cancer diagnoses was found to decrease. When viewed in terms of screening efficiency, the number of colposcopies performed to detect a single case of CIN3/AIS increased in the cohort with repeat screening. CONCLUSIONS: Repeated cotesting at a 3-year interval eventually lowers population rates of precancer and cancer. However, a greater number of colposcopies are required to detect a single precancer. Cancer 2016;122:3682-6.

KW - biopsy

KW - cervical cancer

KW - cervical intraepithelial neoplasia

KW - colposcopy

KW - cotest

KW - human papillomavirus

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=84995770352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995770352&partnerID=8YFLogxK

U2 - 10.1002/cncr.30277

DO - 10.1002/cncr.30277

M3 - Article

VL - 122

SP - 3682

EP - 3686

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -